Shared insight on the current state of HER2 classification and testing and in breast cancer, with respect to how it may influence future treatment approaches.
Post-Conference Perspectives: Understanding HER2-Low Breast Cancer
Focused discussion on the methods used to identify a patient’s HER2 status and why it is important to investigate in patients with breast cancer.
Experts take a look at clinical data behind novel antibody drug conjugates and consider how they may impact the management of HER2-low breast cancer.
Practical considerations for the sequencing or combination of novel antibody drug conjugates to optimize outcomes for patients with HER2-low breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
3
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5